

The four ESG materialities aim to contribute to the sustainable development of society and improving Santen's medium-to-long-term corporate value. We have presented specific issues to promote and disclose the activities and the progress of our efforts as needed on the Company's website.

| ESG Materiality | Priority Item | Main Objectives for 2025 |
|---|--|---|
| Development and Stable Supply of Socially Significant Products and Services ("Happiness with Vision") | Market Penetration of Products with Social Significance | Improving the quality and quantity of ophthalmic care around the world, including developing and poorest countries, and contributing to the reduction of the number of non-treated patients by improving access to healthcare in ophthalmology Reaching ≥60 million patients¹ Fulfilling social responsibility throughout the supply chain Identifying critical suppliers and implement CSR procurement including suppliers of indirect materials and secondary suppliers Thorough pharmacovigilance and enhancement of customer service Production and supply capacity of 500 million or more |
| | Evaluation and Management of the Supply Chain | |
| | Assurance of Quality and Safety, and Establishment of an Appropriate Supply System | |
| | Provision of Appropriate Information on Products and Services | |
| Encouragement of an Organizational Culture that Promotes Value Creation | Promotion of Diversity, Equity & Inclusion | Improving understanding and awareness of employees toward blindness and visual impairment. Providing opportunities to share work and values with people that have visual impairments throughout the Group Increase diverse representation with a focus on gender, nationality at all levels, especially senior management Promote employment opportunities for people with disabilities, including vision impairment throughout the Group Promotion of Diversity, Equity and Inclusion (Page 38) |
| | Building a High-Value-Added and Highly Productive Work Environment | |
| | Human Resource Development | |
| Strengthening Governance, Contributing to the Realization of Fair and Equal Society | Corporate Governance | Increased diversity in the Board of Directors Development of Group risk management system, development and penetration of related regulations, strengthening of cooperation with the risk management department and internal control defense line related departments Establish the PDCA cycle for continuous verification and improvement of the risk management system through close cooperation between related departments functions Appropriately responding to security risks and ensuring a system for business continuity even when faced by unexpected events Formulate a disaster recovery framework and planning |
| | Compliance | |
| | Risk Management | |
| | Respect for Human Rights | |
| Conservation of the Global Environment | Measures against Climate Change | Contribution to realization of a carbon-free society and establishment of a recycling-based society through measures against climate change, measures for water resource and resource saving, and measures against plastic Conservation of the Global Environment (Page 44) |
| | Environmental Load Reduction | |

¹ Estimated total number of patients to whom Santen has contributed (therapeutic areas: inflammation/allergies, cornea disorders, glaucoma, cataracts) as of FY2019 was approx. 43 million, calculated based on JMDC's estimated total number of patients for Santen's Rx products and Santen's shipment data

For more details on ESG materiality, see the Company's website.







